In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit 
Introduction
Influenza, an acute respiratory infectious disease caused by influenza viruses, remains a serious public health problem worldwide, despite the availability of antiviral drugs and vaccines (Rolfes et al., 2016) . Also, the increase of zoonotic diseases with avian influenza viruses are of growing concern (Zhou et al., 2017) . Although neuraminidase inhibitors (NAIs) are the mainstay of antiviral treatment for influenza infections, an epidemic of NAI resistant viruses such as NA/ H274Y has been reported (Sheu et al., 2008) . Therefore, antiviral drugs with a novel mechanism of action are urgently needed.
The heterotrimeric influenza RNA polymerase, comprising subunits PA, PB1 and PB2 protein, plays an essential role in the viral replication and transcription. The transcription of viral mRNAs depends on a unique "cap-snatching" mechanism. In the initial step, PB2 binds to the host nascent capped transcripts, followed by cleavage at a position approximately 12 nucleotides from the 5′-cap by a cap-dependent endonuclease (CEN) to generate a primer. The short capped primers are utilized for viral mRNA synthesis by RNA-dependent RNA polymerase (RdRp) activity of the PB1. These processes are all crucial for the viral RNA transcription and are considered to be promising anti-influenza targets. In fact, the influenza A virus-specific PB2 cap-binding inhibitor pimodivir (Pflug et al., 2018) and the PB1 RdRp inhibitor favipiravir (Furuta et al., 2002) are currently under development or in limited use in clinical settings.
The CEN in the PA subunit uses divalent metal ions for its activity (Dias et al., 2009; Yuan et al., 2009) . CEN inhibitors (CENi) with a metal ion-binding structure have been reported (Cianci et al., 1996; Bauman et al., 2013; Miyagawa et al., 2016; Jones et al., 2018) . BXA (formerly S-033447), the active form of the prodrug BXM (formerly S-033188), is a first-in-class, small-molecule CENi, that is approved in Japan for the treatment of influenza type A and B virus infections, and is under regulatory review in the United States. BXA was generated by rational molecular design based on the original two-metal pharmacophore concept for dolutegravir, a human immunodeficiency virus (HIV) integrase inhibitor (Johns et al., 2013) . As dolutegravir utilizes the two divalent metal ions for binding to the HIV integrase active site, we proposed that the metal-binding scaffold of dolutegravir might be transferred to design CENi. Here, we describe the in vitro characterization of a novel CEN inhibitor, BXA. The results show that BXA is highly selective with broad potency against various types of influenza viruses.
Materials and methods

Compounds
BXA and BXM were synthesized at Shionogi & Co., Ltd., Osaka, Japan (Fig. 1) . Suramin sodium salt and ribavirin were purchased from Sigma-Aldrich Co., Ltd. (Tokyo, Japan). Oseltamivir acid and laninamivir were obtained from Toronto Research Chemicals Inc. (Toronto, Canada) . Zanamivir hydrate and favipiravir were purchased from Sequoia Research Products Ltd. (Pangbourne, UK) and PharmaBlock Sciences, Inc. (Nanjing, China), respectively.
Enzyme inhibition assays
Preparation of capped RNA substrates
Twelve-or 30-mer oligoribonucleotides triphosphorylated at the 5′ terminal and cy3-labeled at position 6 were synthesized by TriLink BioTechnologies (San Diego, CA). The 5′ terminal of each oligo-ribonucleotide was capped and methylated using the ScriptCap™ System (CELLSCRIPT, Madison, WI), and the products were purified by polyacrylamide gel electrophoresis. The resulting sequences of RNA substrates are as follows: CN701 (5′-Cap-8AA UA5 GCA UCA-3′) and CN560 (5′-Cap-8AA UA5 GCA UCA CUA GUA AGC UUU GCU CUA-3′), where 8 and 5 indicate 2′-O-methyl-G and cy3-labeled U, respectively.
Inhibition assay of viral RNA transcription using recombinant viral RNA polymerase complex
Tandem affinity purification (tap)-tagged heterotrimeric viral RNA polymerase complex (3Ptap) was expressed in mammalian cells and purified as reported previously (Deng et al., 2005) . Briefly, Expi 293-F cells (Thermo Fisher Scientific Inc., Massachusetts, USA) were transfected with expression plasmids of PB1, PB2tap and PA, in which the PB2 subunit had been tap-tagged at the C-terminus. Cells were cultured at 37°C for 3 days in an 8% CO 2 incubator, and the extracts were chromatographically purified. The protein A-bound proteins were washed with buffer containing 1 mM dithiothreitol (DTT), 1.2 M NaCl, 10% glycerol, 0.05% polyoxyethylene (20) sorbitan monolaurate solution (Tween 20), 20 mM HEPES (pH 8.0), and then released by cleavage with tobaccoetch virus protease (Thermo Fisher Scientific Inc., Massachusetts, USA). The 3Ptap proteins served as a source of CEN, RdRp, or CEN/RdRp (sequential reaction of CEN and RdRp) activities and were used for the viral RNA transcription assay (Fodor et al., 2002) .
CN560 was used as a substrate for the CEN assay, and the enzymatic reaction was performed in a reaction buffer [1 mM MgCl 2 , 50 mM NaCl, 1 mM DTT, 0.05% Tween 20, 4 U/μL recombinant RNase inhibitor (TaKaRa Bio Inc., Shiga, Japan), 3 nM of the capped RNA substrate, 0.8 μM of the 5' (5′-AGUAGAAACAAGGCC-3′) and 3' (5′-GGCCUGCU UUUGCU-3′) vRNAs (Fodor et al., 2002) and 50 mM Tris-HCl (pH 7.8)]. For the RdRp and CEN/RdRp assays, CN701 and CN560 were used as the substrate, respectively, and the reaction was performed in the reaction buffer in the presence of 0.1 mM each of ATP, GTP, CTP and UTP (NTP; Roche Diagnostics, Rotkreuz, Switzerland). Experimental conditions for CEN, RdRp and CEN/RdRp assays were the same except for the substrates used in each assay (capped RNA and NTP). Each reaction mixture was incubated at 37°C for 1 h followed by adding excess EDTA to stop the reaction, the products were examined using an Applied Biosystems ® genetic analyzer 3130xl, and relatively quantitated using GeneMapper ® v4.1 software. The basics and RNA fragments in the assays are shown in Fig. S1 . A 15-nucleotide-sized marker in GeneScan™ −120 LIZ ™ was used as an internal standard for relative quantitation by GeneMapper ® v4.1 software. The drug concentration achieving 50% inhibition of the enzymatic production (IC 50 ) was calculated by dividing the peak area of the cy3-labeled enzymatic product by the peak area of the internal standard. T. Noshi et al. Antiviral Research 160 (2018) (Klumpp et al., 2001) . Ten day old embryonated chicken eggs were inoculated with 0.2 mL of virus dilutions [2-20 plaqueforming unit (PFU)/mL]. After incubation at 37°C for 2 days, the allantoic fluid of the chicken egg was recovered. Virus particles were purified by ultracentrifugation using 20% sucrose, and solubilized using Triton X-100 (Merck KGaA, Darmstadt, Germany) and lysolecithin (Avanti Polar Lipids, Alabama, USA). vRNP fractions (50-70% glycerol fraction) were collected by ultracentrifugation (Beckman-Coulter Optima EX-90) at 125,000 g at 4°C for 90 min, and were used as sources of CEN activity. The reaction was performed in the reaction buffer in the absence of 5′ and 3′ vRNAs. The other assay conditions and procedures were the same as those of the CEN assay described in section 2.2.2.
Cells and viruses
Madin-Darby canine kidney (MDCK, European Collection of Cell Cultures, Wiltshire, UK), Madin-Darby bovine kidney (MDBK, DS Pharma Biomedical Co., Ltd., Osaka, Japan), and human nasal RPMI2650 cells (American Type Culture Collection, Manassas, VA) were maintained in minimum essential medium (MEM) (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (SigmaAldrich Co., Ltd.). Human alveolar adenocarcinoma A549 cells (European Collection of Cell Cultures) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Thermo Fisher Scientific) with 10% FBS. All the influenza virus strains were propagated in MDCK cells or embryonated chicken eggs, and infectious titers were determined by standard tissue culture infectious dose (TCID) 50 or PFU assays in MDCK cells.
Virus yield reduction assay
MDCK cells seeded in 96-well plates were infected with the indicated viruses at 100 TCID 50 /well. The cells were cultured with 3 μg/ mL trypsin at 37°C for seasonal strains or 2.5 μg/mL trypsin at 35°C for zoonotic strains, except for A/Hong Kong/483/97 (H5N1) strain without trypsin at 35°C. At 24 h and 30 h post-infection with influenza A and B viruses, respectively, the culture supernatants were collected and virus titers (TCID 50 /mL) were determined. The EC 90 was calculated as the concentration decreasing the virus titers to one-tenth of the untreated control values.
Plaque reduction assay
MDCK cells seeded in 12-well plates were infected with approximately 50 PFU/well of test strains. Following incubation at 33°C in a CO 2 incubator for 1 h, the cells were overlaid with virus assay medium containing the test substances, 0.8% Difco Agar Noble (Becton, Dickinson and Company, Franklin Lakes, NJ) and 3 μg/mL trypsin. After incubation for 3 days at 33°C, the cells were fixed and stained with 0.5% amido black solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and plaque numbers were counted under a microscope. The drug concentration achieving 50% inhibition (EC 50 ) by means of plaque number was calculated.
Cytopathic effect (CPE) inhibition assay
MDCK cells in 96-well plates were infected with the indicated viruses at 50 TCID 50 /well and cultured in medium containing the compound and 3 μg/mL trypsin. Cell viability was assessed after 6 days using a WST-8 proliferation assay kit (Kishida Chemical Co., Ltd., Osaka, Japan), followed by determination of the EC 50 value by means of viability of the cells. The 50% cytotoxicity concentration (CC 50 ) was 
Inhibition assay of viral RNA synthesis
MDCK cells in 96-well plates were infected with A/WSN/33 virus at a multiplicity of infection (MOI) of 5 TCID 50 /cell. The infected cells were treated with serial 5-fold dilutions of inhibitors, and cultured in the medium containing 3 μg/mL trypsin at 37°C in a 5% CO 2 incubator. At 5 h post-infection, the culture supernatant was removed and the RNA was extracted from the infected cells. The expression levels of viral mRNA, vRNA, and cRNA of the nucleoprotein segment were quantified as described (Kawakami et al., 2011) . As an internal control, canine 18S rRNA level was quantified (Hamamoto et al., 2013) , followed by calculation of relative levels of viral mRNA, vRNA and cRNA.
Isolation and characterization of resistant variants
MDBK cells were initially infected with A/WSN/33 virus at an MOI of ∼0.01 PFU/cell, and cultured for 3 days in triplicate with BXA at 0.02-12.5 nM to cover the EC 50 of BXA (∼0.5 nM). The culture supernatants were sequentially passaged through fresh MDBK cells at an MOI of ∼0.01 PFU/cell in the presence of doubling concentrations of BXA. The passages were terminated when the titer of the stored culture fluid was too low for infection at an MOI of 0.01 PFU/cell. Viruses from the final passage were propagated once in the absence of BXA, and the BXA susceptibility of the isolated viruses was evaluated by a plaque reduction assay using MDBK cells. The viral RNAs were extracted, and Sanger sequencing was performed to determine the amino acid sequence of the PA, PB1, PB2, HA and NA proteins. Recombinant A/ WSN/33 viruses were generated by plasmid-based reverse genetics (Hoffmann and Webster, 2000) . To assess the replicative capacity of the viruses, MDBK, MDCK, RPMI2560 or A549 cells were infected with 100 TCID 50 /well of the viruses on 24-well culture plates, and then the culture supernatants were collected at indicated the time points, followed by titration in MDCK cells.
Results
Inhibition of cap-dependent endonuclease activity by BXA
To assess the inhibitory effects of BXA on CEN and RdRp activities as well as the sequential reaction of CEN and RdRp (CEN/RdRp), recombinant 3Ptap derived from A/WSN/33 (H1N1) was subjected to a transcription assay (Fig. S1 ). BXA inhibited CEN and CEN/RdRp activities with mean IC 50 of 2.5 and 1.6 nM, respectively, while low potency (IC 50 > 40 nM) was observed against RdRp activity ( Table 1) , suggesting that BXA selectively inhibits CEN activity. BXM, the prodrug form of BXA (Fig. 1 ) exhibited more than 200-fold lower inhibitory activity. We next employed the vRNPs in the enzyme assays, which were purified from influenza A and B viral particles. We found that BXA had a high inhibitory potency against CEN activity of the tested vRNPs from influenza A and B viruses with mean IC 50 values of 1.4-3.1 nM and 4.5-8.9 nM, respectively (Table 2), indicating that BXA has broad spectrum activities. To confirm the specificity of BXA's inhibitory activities, the suramin sodium salt, a non-specific inhibitor of enzymesubstrate binding (Farnet et al., 1996) , was used as a control compound (Fig. S1C) , and showed non-specific inhibition as expected. These results demonstrated that BXA inhibits virus RNA transcription via selective CEN inhibition in enzymatic assays.
Potent and broad activities of BXA in infected cells
To compare the antiviral potency of BXA with the marketed antiinfluenza drugs in infected cells, yield reduction assays were performed with 8 laboratory strains, covering influenza A and B viruses, and including a NAI-resistant strain. BXA showed high potency against influenza A and B viruses with mean EC 90 of 0.46-0.98 nM and 2.2-3.4 nM, respectively, whereas the other compounds tested exhibited a lower potency than that of BXA (Table 3) . NA/H274Y in A/ WSN/33 conferred resistance to oseltamivir acid, but the potency of BXA was unaffected by the substitution.
Concentration-dependent antiviral activity of BXA against A/WSN/ 33, B/Hong Kong/5/72 and A/WSN/33-NA/H274Y in comparison with other marketed drugs revealed that BXA exhibited a steep dose-response curve compared to NAIs, which resulted in a 2-3 log 10 yield reduction at nano-molar concentrations against tested viruses (Fig. 2) . Favipiravir also showed a steep dose-response, but the concentration range for the yield reduction was higher than BXA.
To evaluate the inhibitory effects of BXA against various types of viruses, clinical isolates and animal-derived influenza viruses were subjected to susceptibility testing. BXA exhibited high potency against clinical isolates from influenza A and B viruses with mean EC 90 values ranging from 0.63 to 0.95 nM and 6.1-6.5 nM, respectively. When tested with various subtypes of animal influenza A viruses (H1N2, H5N1, H5N2, H5N6, H7N9, and H9N2), the inhibitory potency of BXA was comparable to the levels seen with H1N1 and H3N2 viruses (Table 3) . Plaque reduction assays were conducted with 33 clinical strains isolated from 2006 to 2014 in Japan, 6 laboratory strains, and 12 vaccine strains recommended by the World Health Organization to further confirm the potency of BXA. The mean EC 50 values of BXA for these strains of influenza A and B viruses, which included a NAI-resistant strain, ranged from 0.20 to 1.9 nM and 3.3-13 nM, respectively (Table S1 ).
The results suggest that BXA has both potent and broad activity against influenza A and B viruses compared to the other marketed drugs, including strains from laboratory, clinical isolates, and recent vaccine strains.
Cytotoxicity and selectivity index of BXA in the cells
To evaluate the margin between antiviral activity and cytotoxicity, the inhibition of BXA on CPE caused by virus replication and the cytotoxicity of BXA were determined in MDCK cells under the same assay conditions. The mean EC 50 values of BXA against influenza A and B viruses ranged from 1.2 to 5.7 nM, and the selectivity index ranged from 520 to 2400 (Table S2 ), suggesting that BXA blocks virus replication without causing significant cytotoxicity.
Inhibitory effects of BXA against viral RNA synthesis
To confirm that BXA targets CEN activity in infected cells, viral mRNA, vRNA and cRNA levels in the presence of BXA were quantified with the A/WSN/33-infected cells. At 5 h post-infection, BXA inhibited viral mRNA, vRNA, and cRNA synthesis in infected cells with mean EC 90 values of 13, 13, and 16 nM, respectively (Fig. 3) . Intriguingly, BXA achieved 4 log 10 reduction in mRNA levels at a lower concentration than favipiravir, which showed mean EC 90 values of 270, 170, and 480 μM for viral mRNA, vRNA and cRNA synthesis, respectively. The lower inhibitory potency of favipiravir against viral RNA synthesis compared to that in viral replication (Fig. 2) may be due to the 5-h treatment not being of sufficient duration for metabolic activation in infected cells (Smee et al., 2009) . No difference in the ratio of EC 90 values against the different types of viral RNAs between BXA and favipiravir was observed. No inhibitory effect on viral RNAs synthesis was detected with oseltamivir acid, confirming that the compounds were evaluated too soon after infection in the single-round replication. The results suggest that BXA blocks viral mRNA, vRNA and cRNA synthesis at the early stage of viral replication in infected cells.
Isolation and characterization of influenza A variants with reduced drug susceptibility
In vitro drug-resistant isolation was conducted to explore amino acid changes that would confer reduced susceptibility to BXA, and provide insight into the mode of action of BXA in infected cells. The MDBK cell line was used in the study, as it is classically known to be highly permissive for viral replication of A/WSN/33 virus (Choppin, 1969) . MDBK cells were initially infected with the viruses at an MOI of 0.01 PFU/cell and cultured in the presence of different concentrations at 0.02, 0.1, 0.5, 2.5 or 12.5 nM, in triplicate per concentration, to cover the EC 50 of BXA (Table S3) , and then the concentration of BXA was increased 2-fold with every sequential passage. Of the 15 samples from the first passage, 5 samples incubated at 2.5 and 12.5 nM of BXA had post-incubation virus titers too low to continue passaging. The remaining 10 samples could be passaged at least 2 times and up to 10 times. Susceptibility testing revealed that the four variants (P6-9-1, P7-9-1, P8-6-1 and P9-6-1), which were isolated after 6-9 passages with the initial passage at 0.02 and 0.1 nM BXA, exhibited reduced susceptibility to BXA by 22-to 41-fold (Table S3 ). Sanger sequencing confirmed that all variants with reduced BXA susceptibility harbored a single isoleucine to threonine substitution at position 38 in the PA protein (PA/I38T). To evaluate the impact of the single PA/I38T substitution on drug susceptibility, we generated rgA/WSN/33-PA/I38T virus by reverse genetics and compared the susceptibility with the P9-6-1 variant in a yield reduction assay. We found that both rgA/WSN/33-PA/I38T and the P9-6-1 variant exhibited comparable reduction in BXA susceptibility by 30-to 40-fold, demonstrating that PA/I38T is the determinant of reduced susceptibility to BXA with the isolated variants ( Table 4 ). The importance of the PA/I38T substitution in influenza A virus has been confirmed by clinical studies (Omoto et al., 2018; Hayden et al., 2018) . These results were in line with the previous observation that the mutant enzyme derived from the PA N-terminal domain bearing PA/I38T exhibited reduced susceptibility to BXA in qualitative assays (Omoto et al., 2018) . In addition, we found that PA/I38T did not affect susceptibility to favipiravir.
The replicative capacity of the PA/I38T viruses with P9-6-1 and P7-9-1 isolated from in vitro passages as well as NAI-resistant viruses bearing the NA/H274Y substitution in MDBK, MDCK, RPMI2650 or A549 cells were assessed. We found that viral titers of PA/I38T variants in the early phase of viral replication were lower when compared to the wild-type and NA/H274Y viruses in all the cell types (Fig. 4 and Fig.  S2 ). In addition, the peak titers of the P9-6-1 and P7-9-1 variants at 48 and 72 h post-infection were markedly lower compared to the wild-type and NA/H274Y viruses, particularly in RPMI2650 and A549 cells derived from the human respiratory tract (Fig. 4C and D) . When reverse genetics-derived PA/I38T viruses were tested, impaired replication fitness was observed in all the cell types. The P7-9-1 variant showed marked decrease of viral fitness in MDCK cells (Fig. 4B) , and therefore exploratory sequencing was conducted with HA, NA, PB1 and PB2 segments, since the replicative capacity may be affected by the functional balance of HA and NA as well as the viral RNA polymerase activity exhibited by PA, PB1 and PB2. Sanger sequencing revealed that the P7-9-1 variant harbors HA/I133M and HA/E507G substitutions compared to the parent virus (Table S4 ). These substitutions might have let to deficient growth of the P7-9-1 variant in MDCK cells. Intriguingly, the P9-6-1 variant showed a comparable level of peak titer compared to the wild-type in MDBK cells although it bears the PA/I38T substitution (Fig. 4A) . Exploratory sequencing showed that the P9-6-1 variant harbors PB2/T129A, PB2/Q288L, HA/I236V, HA/T358N, and NA/T269A substitutions in addition to PA/I38T (Table S4 ). These substitutions might have a role in compensating for the impaired replicative capacity of PA/I38T viruses in MDBK cells, perhaps by interacting bovine specific host factors (Watanabe et al., 2014) . Because severe growth impairment of A/WSN/33 viruses was observed when compared to the reverse genetics-derived rgA/WSN/33 in A549 cells (Fig. 4D) , the amino acids of HA, NA, PB1 and PB2 proteins were compared. We found a number of differences in amino acids between naïve A/WSN/33 and rgA/WSN/33 viruses (Table S4) , leading us to conclude that the polymorphic amino acids might have influenced the replicative capacity in A549 cells. Taken together, the data indicate that the PA/I38T substitution in the A/WSN/33 strains resulted in reduced replication fitness compared to the wild-type; the compensatory substitutions that lead to recovery of the impaired replicative capacity of PA/I38T viruses in human cells could not be identified. The body of evidence obtained in this study supports the mode of action of BXA as a CEN inhibitor in infected cells (Fig. 5) .
Discussion
In the present study, we conducted in vitro characterization of BXA, the active form of BXM. The enzyme inhibition assay mimicking the "cap-snatching" process showed that BXA selectively blocked CEN activity in viral RNA transcription. Given that BXA did not inhibit RdRp activity while cap-binding of PB2 to the RNA substrate is required for exhibiting both CEN and RdRp activities, it has been suggested that BXA does not interfere with PB2-cap binding (Byrn et al., 2015) . The phenolic hydroxy group and two adjacent carbonyl groups of BXA bind to the active site of CEN, which exhibits the enzyme inhibitory activity (Omoto et al., 2018) . Therefore, the prodrug BXM, which masks the phenolic hydroxy group, showed a lack of potent activity in the CEN assay. The importance of the phenolic hydroxy group for metal-chelating in the CEN active center was also supported by structure-activity relationship of inhibitors against various metalloenzymes (Rogolino et al., 2012) . The results indicate that BXA is a selective inhibitor of CEN in the PA subunit.
BXA inhibited CEN activity of vRNPs from influenza A and B viruses in enzymatic assays, and also exhibited broad antiviral potency against various types of influenza viruses, regardless of year, region, or host (human, avian, and swine). In addition, it is reported that EX413 (Fig.  S3) , a prototypic compound of BXA in our chemical library [patent WO2010147068A1; also termed RO-7 (Jones et al., 2016) ], showed antiviral activity with broad spectrum. The broad spectrum of activity could be explained by high conservation of amino acids forming the CEN active center across seasonal, pandemic, and highly pathogenic (2) Fusion/Uncoating. Following internalization, endosomal acidification activates the M2 proton channel, and induces HA conformational changes, which lead to fusion between the virion and endosomal membranes, resulting in release of the vRNPs into the nuclei. (3) Transcription. Viral mRNA transcription occurs through a unique "cap-snatching" mechanism. In the initial step, the PB2 subunit binds to the host nascent capped transcripts (pre-mRNA), followed by cleavage at a position of approximately 12 nucleotides by the cap-dependent endonuclease (CEN) in the PA subunit. The capped primers serve as primers for viral mRNA synthesis by RNAdependent RNA polymerase (RdRp) activity of the PB1 subunit. The viral mRNAs are exported to the cytoplasm and translated into the viral proteins. (4) Replication. After the translation and nuclear entry of PB2, PB1, PA and NP, replication of vRNA can ensue. (5) Budding. Progeny vRNPs are then exported to the cytoplasm and trafficked to the plasma membrane, leading to incorporation into progeny virus particles. Virus release from the plasma membrane is mediated by M2 and NA proteins: M2 promotes scission of budding viruses from the plasma membrane, whereas neuraminidase (NA) prevents virus aggregation at the cell surface. (6) Release/Liberation. The newly produced viral progenies are ready to infect other nearby cells or be transmitted to other hosts. avian influenza viruses (Dias et al., 2009; Yuan et al., 2009) . It was previously reported that the most common amino acid at position 38 in the PA is isoleucine (99.9%), as well as other amino acids such as valine (0.05%), methionine (0.02%) and threonine (0.02%) in 4352 of A(H1N1)pdm09 strains (Stevaert et al., 2013) . BXA sensitivity to polymorphic PA/V38 variants was confirmed with A/swine/Chiba/14/ 2012 (H1N2) and A/chicken/Taiwan/K703-1/2008 (H5N2). Although PA/I38T variants were isolated by sequential passages in the presence of BXA, the frequency of polymorphic PA/T38 in 4352 of A(H1N1) pdm09 strains was only 0.02% (Stevaert et al., 2013) , suggesting that PA/I38 is highly conserved in currently circulating influenza viruses, and the amino acid change at position 38 perhaps occurs only in the presence of BXA.
Interestingly, BXA and favipiravir exhibited a steeper inhibition slope over a wide dynamic range compared with NAIs. BXA also achieved a 2-3 log 10 reduction in viral titers at nano-molar concentrations. Consistent with this, BXA drastically reduced viral mRNA, vRNA and cRNA synthesis. Favipiravir, as expected, showed certain levels of reduction in viral RNAs. Considering that both BXA and favipiravir block an early phase of the viral replication cycle, the mode of action targeting the RNA polymerase complex might account for differences in the dose-response curves. Further studies are important to understand the mechanism of the steeper inhibition and its relationship with inhibitory effects in animal models or in a clinical setting.
The mode of action of BXA in infected cells was demonstrated by the isolation and characterization of PA/I38T variants with reduced sensitivity to BXA. PA/I38T was also identified as a resistance marker of a prototype of BXA in vitro (Jones et al., 2018) . Notably, the results are consistent with the BXM treatment-emergent variant being monitored in clinical studies in which PA/I38T was detected as a major pathway for reduced susceptibility to BXA (Omoto et al., 2018; Hayden et al., 2018) . The mechanism was supported by the cocrystal structures of wild-type and I38T of the PA N-terminal domain bound to BXA, which showed that the mutation reduces van der Waals contacts with the inhibitor (Omoto et al., 2018) .
In conclusion, our results to date demonstrate the high potency of BXA with broad-spectrum coverage of various types of influenza viruses. Lines of evidence indicate that BXA selectively blocks CEN of the influenza virus PA subunit. The results shown here provide in vitro characteristics of the recently marketed drug BXM and support clinical use of BXM for treatment of influenza.
